ANGIODYNAMICS (ANGO) Company Report

James C. Clemmer, President and Chief Executive Officer of AngioDynamics, Inc., will retire from the company, effective November 30, 2026, or earlier upon the appointment of a successor Chief Executive Officer.
A Transition and Retirement Agreement was entered into with Mr. Clemmer on February 3, 2026, which includes provisions for the continued vesting of his equity awards until the termination of his service as a consultant or director.
In connection with Mr. Clemmer's retirement, AngioDynamics approved retention agreements for its executive leadership team (excluding Mr. Clemmer) on January 30, 2026.
These retention agreements offer a cash retention award to eligible executives who remain employed until the earlier of six months from the new CEO's start date or June 1, 2027.
The cash retention awards for named executive officers range from 50% to 150% of their annual base salary, depending on the individual.

1 day ago

8-K

AngioDynamics Announces Cardiovascular Scientific Forum and Recent FDA Milestones

ANGO

Product Launch

New Projects/Investments

AngioDynamics will host its third Cardiovascular Scientific Forum from February 6–8, 2026, in Fort Lauderdale, Florida, to convene cardiovascular physicians and researchers to review emerging data and align on research pathways for the company’s cardiovascular pipeline.
In November 2025, the company received FDA approval for its IDE application for the APEX-Return pivotal study, which will evaluate the AlphaReturn Blood Management System with the AlphaVac F1885 Multipurpose Mechanical Aspiration (MMA) System in patients with acute intermediate-risk PE.
Also in November 2025, AngioDynamics received FDA 510(k) clearance for a modified AlphaVac F1885 System, expanding its indications for use across venous thromboembolism (VTE) procedures, including the treatment of PE.
The company secured FDA IDE approval in November 2025 for the PAVE (Percutaneous AngioVac Vegetation Extraction) pilot study, evaluating the AngioVac System for the percutaneous removal of right-heart vegetations in patients with right-sided infective endocarditis.

1 day ago

Press Release

AngioDynamics Highlights MedTech Growth and CEO Retirement at J.P. Morgan Conference

ANGO

CEO Change

Product Launch

Revenue Acceleration/Inflection

AngioDynamics has completed a five-year transformation to focus on its MedTech portfolio, which has achieved a 25% CAGR and now represents over 45% of total revenue, projected to exceed 50% by FY 2027.
The company's MedTech products, including Auryon (projected to generate over $60 million in revenue this year) and NanoKnife (which received FDA indication in December 2024 and a CPT-1 code on January 1, 2026, for intermediate risk prostate cancer), are driving growth.
AngioDynamics is expected to be cash flow positive for the fiscal year ending May 31, 2026, and currently holds zero debt.
CEO Jim Clemmer announced his retirement from the company this calendar year, initiating a search for a new leader.

Jan 14, 2026, 11:00 PM

Transcript

AngioDynamics Highlights MedTech Growth and Announces CEO Retirement

ANGO

CEO Change

Guidance Update

Revenue Acceleration/Inflection

AngioDynamics has undergone a five-year transformation to focus on a MedTech portfolio in cardiovascular disease and solid tumor cancer, achieving a five-year CAGR of approximately 25% in this segment.
The company's key MedTech products, including Auryon for PAD, AlphaVac for PE, and NanoKnife for prostate cancer, are driving growth, with NanoKnife recently receiving CPT I code approval as of January 1, 2026.
AngioDynamics is now generating positive EBITDA and expects to be cash flow positive for the fiscal year ending May 31, 2026, with zero debt on its balance sheet, and has raised its full-year guidance.
CEO Jim Clemmer announced his retirement from the company this calendar year, with a search process initiated for his successor.

Jan 14, 2026, 11:00 PM

Transcript

AngioDynamics CEO Jim Clemmer Announces Retirement; Company Reports Strong MedTech Growth and Positive Financial Outlook

ANGO

CEO Change

Guidance Update

New Projects/Investments

Jim Clemmer, CEO of AngioDynamics, announced his retirement from the company, effective later in calendar year 2026, after nearly 10 years in the role.
AngioDynamics has undergone a five-year transformation, divesting non-core businesses to focus on its MedTech portfolio, which has achieved a 25% CAGR.
The company's MedTech portfolio includes Auryon, which is up nearly 20% year-to-date , and NanoKnife, which received FDA clearance in December 2024 and a CPT-1 code on January 1, 2026, for intermediate-risk prostate cancer.
AngioDynamics raised its full-year guidance and expects to be cash flow positive for the fiscal year ending May 31, 2026, with increasing EBITDA and free cash generation in subsequent years.
The company plans to drive future growth through internal pipeline expansion into new markets such as BPH, DVT, and the coronary market, rather than through M&A.

Jan 14, 2026, 11:00 PM

Transcript

AngioDynamics provides FY2026 financial outlook and strategic update at J.P. Morgan Healthcare Conference

ANGO

Guidance Update

New Projects/Investments

AngioDynamics, Inc. President and CEO, James Clemmer, presented at the J.P. Morgan 44th Annual Healthcare Conference on January 14, 2026.
The company increased its FY2026 financial guidance for Net Sales to $312 - $314 million and Adjusted EBITDA to +$8.0 - $10.0 million.
AngioDynamics reported a strong balance sheet with $41.6 million in cash as of November 30, 2025, and zero debt.
The company is focused on sustained profitable growth in key MedTech markets, including Prostate Care, Peripheral Artery Disease, and Venous Thromboembolism, supported by products like Auryon, AlphaVac, and NanoKnife.

Jan 14, 2026, 12:33 PM

8-K

AngioDynamics Reports Strong Q2 FY2026 Results, Raises Full-Year Guidance, and Announces CEO Retirement

ANGO

Earnings

Guidance Update

CEO Change

AngioDynamics reported Q2 FY2026 revenue of $79.4 million, an 8.8% increase year-over-year, primarily driven by 13% growth in Med Tech revenue to $35.7 million.
The company achieved an Adjusted EBITDA of $5.9 million in Q2 FY2026, nearly doubling the prior year's Q2, and improved its gross margin by 170 basis points to 56.4%.
AngioDynamics raised its full-year FY2026 guidance for net sales to a range of $312-$314 million and Adjusted EBITDA to $8 million-$10 million.
The company announced three regulatory milestones for its mechanical thrombectomy portfolio, including IDE approvals for the APEX Return and PAVE studies, and 510(k) clearance for a modified AlphaVac F1885 system.
President and CEO Jim Clemmer announced his intention to retire, with a successor expected to be appointed during fiscal 2027.

Jan 6, 2026, 1:00 PM

Transcript

AngioDynamics Reports Strong Q2 2026 Results, Raises Guidance, and Announces CEO Retirement

ANGO

Earnings

Guidance Update

CEO Change

AngioDynamics reported strong Q2 fiscal year 2026 results, with revenue increasing 8.8% to $79.4 million and adjusted EBITDA nearly doubling year-over-year to $5.9 million.
The company raised its full-year fiscal 2026 guidance, now expecting net sales in the range of $312-$314 million and adjusted EBITDA between $8 million-$10 million.
Key product performance included Auryon's 18th consecutive quarter of double-digit growth (18.6% increase), AlphaVac's 40.2% year-over-year increase, and NanoKnife revenue growing 22.2%, primarily driven by prostate procedures.
CEO Jim Clemmer announced his intention to retire, with a search for his successor underway, and the company confirmed the resolution of long-standing port patent litigation with C.R. Bard.

Jan 6, 2026, 1:00 PM

Transcript

AngioDynamics Reports Strong Q2 FY26 Results, Raises Full-Year Guidance, and Announces CEO Retirement

ANGO

Earnings

Guidance Update

CEO Change

AngioDynamics reported strong second quarter fiscal year 2026 results, with revenue growing 8.8% to $79.4 million and adjusted EBITDA nearly doubling year over year to $5.9 million.
The company raised its full-year fiscal year 2026 guidance, now projecting net sales between $312-$314 million and adjusted EBITDA between $8 million-$10 million.
Key product lines demonstrated robust growth, including Auryon with 18.6% growth and NanoKnife with 22.2% growth, while the mechanical thrombectomy portfolio achieved three significant regulatory milestones.
CEO Jim Clemmer announced his intention to retire, with a successor expected to be appointed during fiscal year 2027.
The U.S. Court of Appeals affirmed the invalidation of C.R. Bard's port patents, eliminating a potential $3 million payment by AngioDynamics.

Jan 6, 2026, 1:00 PM

Transcript

AngioDynamics Reports Q2 FY 2026 Results, Updates Guidance, and Announces CEO Retirement

ANGO

Earnings

Guidance Update

CEO Change

AngioDynamics reported net sales of $79.4 million for Q2 FY 2026, representing an 8.8% year-over-year growth. Med Tech segment sales grew by 13.0% to $35.7 million, and Med Device segment sales increased by 5.6% to $43.8 million.
The company increased its full-year FY 2026 net sales guidance to $312 - $314 million (from $308 - $313 million) and Med Device Net Sales Growth guidance to +0-1% (from Flat). Adjusted EBITDA guidance was also increased to +$8.0 - $10.0 million (from +$6.0 - $10.0 million).
Jim Clemmer, President and CEO, announced his intention to retire during fiscal 2027 upon the appointment of a successor, with a search committee established by the Board.
AngioDynamics ended Q2 FY 2026 with $41.6 million in cash and zero debt, having generated approximately $4.7 million of cash in the quarter.